John Nemunaitis, MD

Executive Medical Director Mary Crowley Cancer Research Center
Dallas, TX

John Nemunaitis, MD, Oncologist and Executive Medical Director of Mary Crowley Cancer Research Centers (MCCRC), has been exploring novel targeted therapies for treating cancer patients for over 20 years.  Dr. Nemunaitis received his BA and MD degrees from Case Western Reserve University in Cleveland, Ohio. He completed his residency at Boston City Hospital and then performed his Hematology and Oncology fellowship at the University of Washington and the Fred Hutchinson Cancer Research Center in Seattle from 1988 to 1993.  Dr. Nemunaitis came to Dallas in 1993 to establish the clinical research program for Texas Oncology Physicians Association.  He later established a not-for-profit translational research program called the Mary Crowley Cancer
Research Centers.  He is a committee member of the Western Institutional Review Board (WIRB).  In 2005, he co-founded a molecular therapeutic/vaccine biotechnology company with GMP manufacturing capacity called Gradalis, Inc.  His research focus involves clinical translational development of DNA based vaccine technology as well as systemic delivery of DNA platforms, particularly RNA interference technology.  Dr. Nemunaitis has authored 307 peer-reviewed publications and 43 book chapters.  He has conducted over 400 FDA regulated trials including investigator-initiated IND trials, overseen FDA sponsored experimental treatment of over 4800 cancer patients at MCCRC, and has carried out 24 government regulatory (FDA, RAC) presentations for biotechnology product development and is inventor or co-inventor on 15 new patents involving novel molecular therapies.
He was also recently elected as a member of the Board of Directors of
the American Society of Gene and Cell Therapy.